alternating electric field treatment doubles time to progression, overall survival

[Lani]

both in vitro and in vivo ie, in experiments and in live people(with glioblastoma, a brain tumor). THE BC CELL LINE USED was her2- but it worked on a collection of cell lines of different cancers and her2+ bc just wasn't tested it seems. Article is OPEN ACCESS ie, free

Electric fields have potential as a cancer treatment [American Institute of Physics]
Healthy cells have regulating mechanisms that generally limit how rapidly they can divide. Skin cells, for example, normally divide about once every 30 days, but they can divide faster in response to a wound that needs healing. Cancer, however, is characterized by cell division that has gone out of control. In cancer cells, the mechanisms that regulate division break down, and the cells spend less time in the quiescent state and more time dividing.
Many chemotherapy drugs work by interfering with the cell-division cycle. The drugs reach healthy cells and cancer cells alike, but they do most of their damage to the cancer cells. Unfortunately, some types of healthy cells divide as rapidly as cancer cells and are badly damaged as well. Such cells are found in bone marrow, the lining of the digestive tract, and hair follicles, so chemotherapy patients often lose their hair and are susceptible to infection. The damage to healthy cells limits the drug dose that a patient can tolerate and therefore limits the treatment's effectiveness.
Yoram Palti, of the Technion-Israel Institute of Technology in Haifa, and his colleagues have demonstrated another way to disrupt cell division: alternating electric fields with intensities of just 1-2 V/cm. The fields they use, with frequencies in the hundreds of kilohertz, were previously thought to do nothing significant to living cells other than heating them. But Palti and colleagues have conducted a small clinical trial showing that the fields have an effect in slowing the growth of tumors.

OPEN ACCESS: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors [Proceedings of the National Academy of Sciences]
We have recently shown that low intensity, intermediate frequency, electric fields inhibit by an anti-microtubule mechanism of action, cancerous cell growth in vitro. Using implanted electrodes, these fields were also shown to inhibit the growth of dermal tumors in mice. The present study extends these findings to additional cell lines [human breast carcinoma; MDA-MB-231, and human non-small-cell lung carcinoma (H1299)] and to animal tumor models (intradermal B16F1 melanoma and intracranial F-98 glioma) using external insulated electrodes. These findings led to the initiation of a pilot clinical trial of the effects of TTFields in 10 patients with recurrent glioblastoma (GBM). Median time to disease progression in these patients was 26.1 weeks and median overall survival was 62.2 weeks. These time to disease progression and OS values are more than double the reported medians of historical control patients. No device-related serious adverse events were seen after >70 months of cumulative treatment in all of the patients. The only device-related side effect seen was a mild to moderate contact dermatitis beneath the field delivering electrodes. We conclude that TTFields are a safe and effective new treatment modality which effectively slows down tumor growth in vitro, in vivo and, as demonstrated here, in human cancer patients.